Foundation Medicine Inc (NASDAQ:FMI) insider Vincent A. Miller sold 2,349 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $64.00, for a total transaction of $150,336.00. Following the sale, the insider now owns 99,484 shares of the company’s stock, valued at $6,366,976. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Foundation Medicine Inc (NASDAQ FMI) traded up $0.45 during midday trading on Wednesday, reaching $63.05. 184,187 shares of the company’s stock traded hands, compared to its average volume of 338,680. The company has a current ratio of 2.24, a quick ratio of 2.03 and a debt-to-equity ratio of 0.47. Foundation Medicine Inc has a twelve month low of $17.10 and a twelve month high of $70.75. The stock has a market capitalization of $2,290.00, a price-to-earnings ratio of -14.11 and a beta of -0.01.

Foundation Medicine (NASDAQ:FMI) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.16. The business had revenue of $42.66 million during the quarter, compared to analyst estimates of $37.99 million. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. The company’s revenue was up 45.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.90) earnings per share. equities analysts expect that Foundation Medicine Inc will post -4.44 earnings per share for the current year.

FMI has been the subject of several analyst reports. Zacks Investment Research lowered shares of Foundation Medicine from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. BidaskClub upgraded shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. Foundation Medicine has a consensus rating of “Hold” and an average price target of $45.33.

Large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Foundation Medicine by 8.2% during the second quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock valued at $25,096,000 after acquiring an additional 47,843 shares during the last quarter. Peregrine Capital Management LLC bought a new position in shares of Foundation Medicine during the third quarter valued at about $13,299,000. TIAA CREF Investment Management LLC raised its stake in shares of Foundation Medicine by 9.8% during the second quarter. TIAA CREF Investment Management LLC now owns 39,000 shares of the company’s stock valued at $1,550,000 after acquiring an additional 3,490 shares during the last quarter. Macquarie Group Ltd. raised its stake in shares of Foundation Medicine by 33.3% during the third quarter. Macquarie Group Ltd. now owns 106,603 shares of the company’s stock valued at $4,285,000 after acquiring an additional 26,603 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Foundation Medicine by 7.4% during the second quarter. Northern Trust Corp now owns 187,714 shares of the company’s stock valued at $7,462,000 after acquiring an additional 12,881 shares during the last quarter. 32.68% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Vincent A. Miller Sells 2,349 Shares of Foundation Medicine Inc (FMI) Stock” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/03/vincent-a-miller-sells-2349-shares-of-foundation-medicine-inc-fmi-stock.html.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.